Literature DB >> 22751940

Cytokine gene expression signature in ovarian clear cell carcinoma.

Nozomu Yanaihara1, Michael S Anglesio, Kazunori Ochiai, Yukihiro Hirata, Misato Saito, Chie Nagata, Yasushi Iida, Satoshi Takakura, Kyosuke Yamada, Tadao Tanaka, Aikou Okamoto.   

Abstract

Cytokine expression in a tumor microenvironment can impact both host defense against the tumor and tumor cell survival. In this study, we sought to clarify whether the cytokine gene expression profile could have clinical associations with ovarian cancer. We analyzed the expression of 16 cytokine genes (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p35, IL-12p40, IL-15, IFN-γ, TNF-α, IL-6, HLA-DRA, HLA-DPA1 and CSF1) in 50 ovarian carcinomas. Hierarchical clustering analysis of these tumors was carried out using Cluster software and differentially expressed genes were examined between clear cell carcinoma (CCC) and other subtypes. Following this examination we evaluated the biological significance of IL-6 knockdown in CCC. Unsupervised hierarchical clustering analysis of cytokine gene expression revealed two distinct clusters. The relationship between the two clusters and clinical parameters showed statistically significant differences in CCC compared to other histologies. CCC showed a dominant Th-2 cytokine expression pattern driven largely by IL-6 expression. Inhibition of IL-6 in CCC cells suppressed Stat3 signaling and rendered cells sensitive to cytotoxic agents. The unique cytokine expression pattern found in CCC may be involved in the pathogenesis of this subtype. In particular, high IL-6 expression appears likely to be driven by the tumor cells, fueling an autocrine pathway involving IL-6 expression and Stat3 activation and may influence survival when exposed to cytotoxic chemotherapy. Modulation of IL-6 expression or its related signaling pathway may be a promising strategy of treatment for CCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751940     DOI: 10.3892/ijo.2012.1533

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  21 in total

1.  IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.

Authors:  Minghua Zou; Xianquan Zhang; Changhua Xu
Journal:  Cell Oncol (Dordr)       Date:  2015-10-28       Impact factor: 6.730

Review 2.  Clear cell carcinoma of ovary and uterus.

Authors:  Rosalind M Glasspool; Iain A McNeish
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 3.  Precision medicine for ovarian clear cell carcinoma based on gene alterations.

Authors:  Takafumi Kuroda; Takashi Kohno
Journal:  Int J Clin Oncol       Date:  2020-02-04       Impact factor: 3.402

4.  Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.

Authors:  Boris Winterhoff; Habib Hamidi; Chen Wang; Kimberly R Kalli; Brooke L Fridley; Judy Dering; Hsiao-Wang Chen; William A Cliby; He-Jing Wang; Sean Dowdy; Bobbie S Gostout; Gary L Keeney; Ellen L Goode; Gottfried E Konecny
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

5.  Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Authors:  Koji Matsuo; Kosei Hasegawa; Kiyoshi Yoshino; Ryusuke Murakami; Takeshi Hisamatsu; Rebecca L Stone; Rebecca A Previs; Jean M Hansen; Yuji Ikeda; Akiko Miyara; Kosuke Hiramatsu; Takayuki Enomoto; Keiichi Fujiwara; Noriomi Matsumura; Ikuo Konishi; Lynda D Roman; Hani Gabra; Christina Fotopoulou; Anil K Sood
Journal:  Eur J Cancer       Date:  2015-07-31       Impact factor: 9.162

6.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Authors:  Chengfei Liu; Yezi Zhu; Wei Lou; Yuanyuan Cui; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2013-10-16       Impact factor: 4.104

7.  DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.

Authors:  Kelly L Bolton; Francesmary Modugno; Ellen L Goode; Julie M Cunningham; Stacey J Winham; Chen Wang; Britta Weiglt; Zhuxuan Fu; Sebastian M Armasu; Bryan M McCauley; Alison H Brand; Yoke-Eng Chiew; Esther Elishaev; Charlie Gourley; Catherine J Kennedy; Angela Laslavic; Jenny Lester; Anna Piskorz; Magdalena Sekowska; James D Brenton; Michael Churchman; Anna DeFazio; Ronny Drapkin; Kevin M Elias; David G Huntsman; Beth Y Karlan; Martin Köbel; Jason Konner; Kate Lawrenson; Elli Papaemmanuil
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-25       Impact factor: 4.090

8.  MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.

Authors:  Yukihiro Hirata; Noriyuki Murai; Nozomu Yanaihara; Misato Saito; Motoaki Saito; Mitsuyoshi Urashima; Yasuko Murakami; Senya Matsufuji; Aikou Okamoto
Journal:  BMC Cancer       Date:  2014-11-03       Impact factor: 4.430

9.  Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.

Authors:  Ronald L Chandler; Jeffrey S Damrauer; Jesse R Raab; Jonathan C Schisler; Matthew D Wilkerson; John P Didion; Joshua Starmer; Daniel Serber; Della Yee; Jessie Xiong; David B Darr; Fernando Pardo-Manuel de Villena; William Y Kim; Terry Magnuson
Journal:  Nat Commun       Date:  2015-01-27       Impact factor: 14.919

10.  Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Authors:  Parvin Ataie-Kachoie; David L Morris; Mohammad H Pourgholami
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.